scholarly journals Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer

2016 ◽  
Vol 119 (5) ◽  
pp. 667-675 ◽  
Author(s):  
Duncan C. Gilbert ◽  
Trinh Duong ◽  
Howard G. Kynaston ◽  
Abdulla A. Alhasso ◽  
Fay H. Cafferty ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Luteinising Hormone ◽  
Advanced Prostate Cancer ◽  
Prostate Adenocarcinoma ◽  
Life Outcomes ◽  
Releasing Hormone ◽  
Patch Trial ◽  
Androgen Suppression

Quality-of-Life Outcomes in Long-Term Survivors of Advanced Prostate Cancer

1998 ◽  
Vol 21 (4) ◽  
pp. 327-332 ◽  
Author(s):  
Mark S. Litwin ◽  
Andrew I. Shpall ◽  
Frederick Dorey ◽  
Thanh-Hai Nguyen
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Advanced Prostate Cancer ◽  
Life Outcomes ◽  
Quality Of Life Outcomes ◽  
Long Term Survivors

Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 5015-5015 ◽  
Author(s):  
K. Miller ◽  
U. Steiner ◽  
A. Lingnau ◽  
U. Keilholz ◽  
U. Witzsch ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Disease Progression ◽  
Median Time ◽  
Advanced Prostate Cancer ◽  
Continuous Group ◽  
Intermittent Therapy ◽  
Continuous Therapy ◽  
Androgen Suppression

5015 Background: Based on results of animal experiments intermittent androgen blockade was suggested to delay progression of advanced prostate cancer to the hormone refractory stage. We conducted a prospective randomized study to compare intermittent with continuous androgen suppression. Methods: This was a multi-centre, randomised, two-arm study comparing treatment with goserelin + bicalutamide (intermittent, group A) vs. goserelin + bicalutamide (continuous, group B). The primary endpoint was time to clinical and/or biochemical progression of the disease despite androgen suppression. Secondary enpoints were survival time, patient’s quality of life (QoL) and toxicity. Patients eligibility criteria were: histologically confirmed adenocarcinoma of the prostate in clinical stage T1–4N1–3M0 or T1–4N0–3M1 (D1 oder D2). After an induction phase of 24 weeks with MAB, 335 patients whose PSA decreased under 4 ng/ml or = 90% from baseline were randomized. Results: About two-thirds of the patients of both the intermittent and the continuous therapy arm (65% versus 66%, ITT population) experienced a clinical and/or biochemical disease progression due to any reason during this study. The median time to disease progression was longer for patients randomised to the intermittent therapy arm (16.6 months) compared with patients randomised to the continuous therapy arm (11.5 months). This difference however was not statistically significant (log rank test, p=0.1758). The median time to death from any cause was 51.4 month in the intermittent arm compared and 53.8 months in the continuous therapy arm (p = 0.658). There were no differences in the incidence of patients with AEs or SAEs or in any other safety parameter between patients treated intermittently and patients treated continuously. Patients’ self-assessment of their overall health and of their sexual activity appeared to be favourable in the intermittent compared with the continuous therapy arm. 88% of all patients treated intermittently experienced more than 50% of the number of treatment days as treatment-free days. Conclusions: Intermittent therapy in D1 and D2 prostate cancer patients appears to be safe and feasible. Off treatment periods are > 40 % and attribute to patients quality of life. No significant financial relationships to disclose.

scholarly journals Long-term follow-up after active surveillance or curative treatment: quality-of-life outcomes of men with low-risk prostate cancer

2017 ◽  
Vol 26 (6) ◽  
pp. 1635-1645 ◽  
Author(s):  
Lionne D. F. Venderbos ◽  
Shafak Aluwini ◽  
Monique J. Roobol ◽  
Leonard P. Bokhorst ◽  
Eric H. G. M. Oomens ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Treatment Quality ◽  
Life Outcomes ◽  
Risk Prostate Cancer ◽  
Low Risk Prostate Cancer ◽  
Long Term Follow Up

67: Quality of Life Outcomes After Salvage Brachytherapy for Locally Recurrent Prostate Cancer

2021 ◽  
Vol 163 ◽  
pp. S31
Author(s):  
Inmaculada Navarro ◽  
Lisa Joseph ◽  
Zhihui (Amy) Liu ◽  
Alejandro Berlin ◽  
Joelle Helou ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Life Outcomes ◽  
Recurrent Prostate Cancer ◽  
Quality Of Life Outcomes ◽  
Salvage Brachytherapy ◽  
Locally Recurrent
Sign in / Sign up

Export Citation Format

Share Document